Recruiting at 35 sites Phase 3 Sickle Cell Disease

Sickle Cell Disease study: Crizanlizumab

Official title A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

ClinicalTrials.gov ID: NCT06439082

What this study is testing

What is Crizanlizumab?

This is an investigational medicine being studied to help reduce pain crises in people with sickle cell disease. It is designed to block a protein called VWF that helps blood cells stick together, which may prevent blockages in small blood vessels.

Also referred to as Adakveo, Ryverna, SEG101.

Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This study is testing whether crizanlizumab (a medicine) works and is safe for people with sickle cell disease who have frequent pain crises.
Who it's for
You may be able to join if you are a teen or adult with sickle cell disease who has frequent vaso‑occlusive crises.
What's involved
You will receive an infusion of crizanlizumab or a pretend treatment. You may keep taking hydroxyurea if you already use it. You will have doctor visits and check‑ups.
Time commitment
The study lasts several months with regular infusion visits and follow‑up appointments.
  • Phase 3: a large, late-stage study
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 12 to 100

You may be able to join if

  • Participants must be aged 12 years and older on the day of signing informed consent.
  • Confirmed diagnosis of SCD by Hb electrophoresis or high-performance liquid chromatography (HPLC) (performed locally or by central laboratory if not...
  • Experienced 4 to 12 VOCs (refer to Section 8.3.1 for study definition of VOC) that are HCP-managed (including VOCs leading to management at a health...
  • If the participant is on HU/HC, they must be taking it for at least 6 months and at stable dose for at least 3 months prior to the Screening visit...

You likely can't join if

  • Fewer than 4 or more than 12 VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote...
  • History of stem cell transplant and/or gene therapy.
  • Received blood products within 30 days prior to Week 1 Day 1 dosing.
  • Any documented history of a clinical stroke or intracranial hemorrhage, or an uninvestigated neurologic finding within the past 12 months before...
  • Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning to undergo an exchange...
  • Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipients of the study drug formulation.

The study team makes the final eligibility decision.

Where it is enrolling

  • Birmingham, Alabama, United States
  • Orange, California, United States
  • Washington D.C., District of Columbia, United States
  • Jacksonville, Florida, United States
  • Augusta, Georgia, United States
  • Riverdale, Georgia, United States
  • Chicago, Illinois, United States
  • Louisville, Kentucky, United States
  • Baltimore, Maryland, United States
  • Flowood, Mississippi, United States
  • The Bronx, New York, United States
  • Greenville, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Philadelphia, Pennsylvania, United States
  • Houston, Texas, United States
  • Salvador, Estado de Bahia, Brazil
  • São Luís, Maranhão, Brazil
  • Campinas, São Paulo, Brazil
  • Ribeirão Preto, São Paulo, Brazil
  • Sao Jose Rio Preto, São Paulo, Brazil

+ 11 more site(s).

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 12 years to 100 years. The study team makes the final eligibility decision.

Where is this trial taking place?

This study is enrolling now at Birmingham, Alabama, United States; Orange, California, United States; Washington D.C., District of Columbia, United States; Jacksonville, Florida, United States; Augusta, Georgia, United States; Riverdale, Georgia, United States and 25 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.